Template:KDRG: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (11 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[User:Kosar Doraghi|Kosar Doraghi, M.D.]][mailto:k.doraghi@yahoo.com] | |||
=Kosar Doraghi, M.D.= | =Kosar Doraghi, M.D.= | ||
==Current Position== | ==Current Position== | ||
'''Associate Editor-in-Chief,''' Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar | '''Associate Editor-in-Chief,''' Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar | ||
| Line 14: | Line 13: | ||
#[[Deucravacitinib]] | #[[Deucravacitinib]] | ||
#[[Ublituximab-xiiy]] | #[[Ublituximab-xiiy]] | ||
#[[futibatinib]] | #[[LYTGOBI- futibatinib]] | ||
#[[Tapinarof]] | #[[Tapinarof]] | ||
#[[Spevigo- spesolimab-sbz]] | #[[Spevigo- spesolimab-sbz]] | ||
| Line 23: | Line 22: | ||
#[[Nirogacestat]] | #[[Nirogacestat]] | ||
#[[Nedosiran]] | #[[Nedosiran]] | ||
#[[Ryzneuta]] | |||
#[[Endocarditis overview]] | |||
#[[Sparsentan]] | |||
#[[BRENZAVVY- bexagliflozin]] | |||
#[[COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)]] | |||
#[[Nirsevimab]] | |||
#[[Xacduro- sulbactam and durlobactam]] | |||
#[[EXXUA]] | |||
#[[Somatrogon-ghla]] | |||
#[[Aprocitentan]] | |||
#[[WINREVAIR]] | |||
#[[Xolremdi]] | |||
#[[Rytelo]] | |||
#[[Chronic obstructive pulmonary disease history and symptoms]] New Guidelines 2024 | |||
#[[Chronic renal failure overview]] New Guidelines 2024 | |||
#[[Clinical assessment of lower extremity peripheral arterial disease]] New Guidelines 2024 | |||
Latest revision as of 18:17, 20 August 2024
Kosar Doraghi, M.D.
Current Position
Associate Editor-in-Chief, Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar
Pages Authored/Co-authored/Collaborated
- NEXOBRID
- RELYVRIO
- Deucravacitinib
- Ublituximab-xiiy
- LYTGOBI- futibatinib
- Tapinarof
- Spevigo- spesolimab-sbz
- Vericiguat
- Dasiglucagon
- Ponesimod
- Lasmiditan
- Nirogacestat
- Nedosiran
- Ryzneuta
- Endocarditis overview
- Sparsentan
- BRENZAVVY- bexagliflozin
- COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)
- Nirsevimab
- Xacduro- sulbactam and durlobactam
- EXXUA
- Somatrogon-ghla
- Aprocitentan
- WINREVAIR
- Xolremdi
- Rytelo
- Chronic obstructive pulmonary disease history and symptoms New Guidelines 2024
- Chronic renal failure overview New Guidelines 2024
- Clinical assessment of lower extremity peripheral arterial disease New Guidelines 2024